Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia's investors include Partners Investment, Innosuisse, GoBeyond, Foundation for Innovation and Technology (FIT), EISMEA.
Cellestia is headquartered in Basel, Switzerland.
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Cellestia is at the Non-equity Assistance stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellestia — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/cellestia. Accessed August 16, 2026.
VCBacked. (2023). Cellestia — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/cellestia
{{cite web |title=Cellestia — Funding & Investors |url=https://www.vcbacked.co/company/cellestia |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated